T2 Biosystems Continues To Expect FY24 Total Sepsis Product Revenue Of $10M - $11M, Representing Growth Of 49% To 64% Y/Y
Portfolio Pulse from Benzinga Newsdesk
T2 Biosystems expects FY24 total sepsis product revenue to be between $10M and $11M, representing a year-over-year growth of 49% to 64%.
July 29, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
T2 Biosystems projects FY24 sepsis product revenue to be between $10M and $11M, indicating a significant year-over-year growth of 49% to 64%.
The projected revenue growth of 49% to 64% for FY24 is a strong positive indicator for T2 Biosystems, suggesting robust demand and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100